Affimed N.V. (AFMDQ)

OTCMKTS · Delayed Price · Currency is USD
0.0200
+0.0020 (11.11%)
At close: Jul 23, 2025
11.11%
Market Cap327.85K
Revenue (ttm)6.29M
Net Income (ttm)-78.04M
Shares Out16.39M
EPS (ttm)-5.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,166
Average Volume76,971
Open0.0180
Previous Close0.0180
Day's Range0.0180 - 0.0200
52-Week Range0.0180 - 5.4800
Beta1.97
RSI30.85
Earnings DateAug 8, 2025

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 76
Stock Exchange OTCMKTS
Ticker Symbol AFMDQ
Full Company Profile

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR Financial Statements

News

There is no news available yet.